BACKGROUND: Vessel injury at the time of Arteriovenous Fistula (AVF) creation may lead to neointimal hyperplasia that impairs AVF maturation. Vonapanitase, a recombinant human chymotrypsin-like elastase family member 1, is an investigational drug under development to improve AVF maturation and patency. The current studies were designed to document vonapanitase effects in human cephalic veins that are used in AVF creation. METHODS: Human cephalic veins were mounted on a perfusion myograph. Vonapanitase 1.2, 4, 13.2, and 40 μg/ml or saline was applied drop wise on the vein followed by saline rinse. Vein segments were cut into rings for elastin content determination by desmosine radioimmunoassay and histology. Fluorescently-labelled vonapanitase was applied to veins and adventitial imaging was performed using laser scanning confocal microscopy. In vivo time course experiments were performed by treating rabbit jugular veins and harvesting 1 h and 4 h after vonapanitase treatment. RESULTS / CONCLUSION: Vonapanitase reduced desmosine content in a dose-related manner. Histology also confirmed a dose-related reduction in elastic fiber staining. Fluorescently-labelled vonapanitase persistently localized to elastic fibers in the vein adventitia. In vivo experiments showed a reduction in desmosine content in jugular veins from 1 h to 4 h following treatment. These data suggest that vonapanitase targets elastin in elastic fibers in a dose related manner and that elastase remains in the vessel wall and has catalytic activity for at least 1 h.
BACKGROUND: Vessel injury at the time of Arteriovenous Fistula (AVF) creation may lead to neointimal hyperplasia that impairs AVF maturation. Vonapanitase, a recombinant humanchymotrypsin-like elastase family member 1, is an investigational drug under development to improve AVF maturation and patency. The current studies were designed to document vonapanitase effects in humancephalic veins that are used in AVF creation. METHODS:Humancephalic veins were mounted on a perfusion myograph. Vonapanitase 1.2, 4, 13.2, and 40 μg/ml or saline was applied drop wise on the vein followed by saline rinse. Vein segments were cut into rings for elastin content determination by desmosine radioimmunoassay and histology. Fluorescently-labelled vonapanitase was applied to veins and adventitial imaging was performed using laser scanning confocal microscopy. In vivo time course experiments were performed by treating rabbit jugular veins and harvesting 1 h and 4 h after vonapanitase treatment. RESULTS / CONCLUSION: Vonapanitase reduced desmosine content in a dose-related manner. Histology also confirmed a dose-related reduction in elastic fiber staining. Fluorescently-labelled vonapanitase persistently localized to elastic fibers in the vein adventitia. In vivo experiments showed a reduction in desmosine content in jugular veins from 1 h to 4 h following treatment. These data suggest that vonapanitase targets elastin in elastic fibers in a dose related manner and that elastase remains in the vessel wall and has catalytic activity for at least 1 h.
Entities:
Keywords:
AVF; Arteriovenous fistula; CELA1; Chymotrypsin-like elastase family member 1; Elastase; Elastin; Hemodialysis access; PRT-201; Vonapanitase
Authors: Philippe G Amabile; Humberto Wong; Marie Uy; Sara Boroumand; Christopher J Elkins; Eser Yuksel; Jacob M Waugh; Michael D Dake Journal: J Vasc Interv Radiol Date: 2002-07 Impact factor: 3.464
Authors: Emma Moss; Sarah Lynagh; Derek Smith; Stuart Kelly; Andy McDaid; David Bunton Journal: J Pharmacol Toxicol Methods Date: 2010-05-10 Impact factor: 1.950
Authors: Robert J Hye; Eric K Peden; Timothy P O'Connor; Barry J Browne; Bradley S Dixon; Andres S Schanzer; Stephen C Jensik; Laura M Dember; Michael R Jaff; Steven K Burke Journal: J Vasc Surg Date: 2014-03-27 Impact factor: 4.268
Authors: Amir A Qamar; Steven K Burke; Jason D Lafleur; Bee C Ding; Kimberly S Bland; Marco D Wong; Pamela N Gustafson; Andrew T Blair; F Nicholas Franano Journal: Biotechnol Appl Biochem Date: 2012-01-02 Impact factor: 2.431
Authors: H Masuda; Y J Zhuang; T M Singh; K Kawamura; M Murakami; C K Zarins; S Glagov Journal: Arterioscler Thromb Vasc Biol Date: 1999-10 Impact factor: 8.311
Authors: Timothy C Boire; Lauren E Himmel; Fang Yu; Christy M Guth; Bryan R Dollinger; Thomas A Werfel; Daniel A Balikov; Craig L Duvall Journal: J Biomed Mater Res A Date: 2020-07-04 Impact factor: 4.854